T2 BIOSYSTEMS,INC. (NASDAQ:TTOO) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial
On May2, 2017, T2 Biosystems,Inc. (the Company) issued a press
release announcing its financial results for its fiscal quarter
ended March31, 2017 and held a conference call to discuss those
results. A copy of the Companys press release and a copy of the
transcript of the conference call are furnished with this report
as Exhibits 99.1 and 99.2, respectively.
In accordance with General Instruction B.2 of Form8-K, the
information in this Item 2.02 and Exhibits 99.1 and 99.2 of this
Current Report on Form8-K are being furnished and shall not be
deemed to be filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section. Furthermore, such information,
including Exhibits 99.1 and 99.2 attached hereto, shall not be
deemed to be incorporated by reference in any filing under the
Securities Act of 1933, as amended, except as expressly stated by
specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
Press Release issued May2, 2017
Transcript of conference call held by T2 Biosystems,Inc. on
About T2 BIOSYSTEMS, INC. (NASDAQ:TTOO)
T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel. T2 BIOSYSTEMS, INC. (NASDAQ:TTOO) Recent Trading Information
T2 BIOSYSTEMS, INC. (NASDAQ:TTOO) closed its last trading session up +0.02 at 3.83 with 135,128 shares trading hands.